Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accurate accounting of caplacizumab cost effectiveness – Authors' reply

Journal article

Hughes M. et al, (2021), The Lancet Haematology, 8

Adjusting for Nonadherence or Stopping Treatments in Randomized Clinical Trials.

Journal article

Adler AI. and Latimer NR., (2021), JAMA, 325, 2110 - 2111

Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.

Journal article

Copland E. et al, (2021), Lancet Oncol, 22, 558 - 570

Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.

Journal article

Copland E. et al, (2021), Lancet Oncol, 22, 558 - 570

The STEP 1 trial for weight loss: a step change in treating obesity?

Journal article

Adler AI., (2021), Nature Medicine, 27, 589 - 590

NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction.

Journal article

Adler AI. et al, (2021), Lancet Diabetes Endocrinol

NICE guidance on caplacizumab for treating acute acquired thrombotic thrombocytopenia purpura.

Journal article

Hughes M. et al, (2021), Lancet Haematol, 8, e14 - e15

Impact of a Global Pandemic on Health Technology Assessment.

Journal article

Lorgelly PK. and Adler A., (2020), Appl Health Econ Health Policy, 18, 339 - 343

Cannabidiol with clobazam for seizures associated with Dravet and Lennox-Gastaut syndromes

Journal article

Lamb A. et al, (2020), The Lancet Neurology, 19, 290 - 291

NICE guidance on sotagliflozin for type 1 diabetes.

Journal article

Adler AI. et al, (2020), Lancet Diabetes Endocrinol, 8, 274 - 275

To treat or not to treat: dysglycaemia in cystic fibrosis.

Journal article

Adler AI., (2019), Diabetic medicine : a journal of the British Diabetic Association, 36, 1365 - 1366

NICE guidance on dapagliflozin with insulin for type 1 diabetes.

Journal article

Adler AI. et al, (2019), The lancet. Diabetes & endocrinology, 7, 750 - 751

Ocrelizumab for primary progressive multiple sclerosis.

Journal article

Adler AI. and Knight H., (2019), The Lancet. Neurology, 18, 816 - 817

Evidence and issues in addressing cost-effectiveness in treating obesity

Journal article

Adler A., (2019), Medicine (United Kingdom), 47, 188 - 189

Fatal squamous cell carcinoma from necrobiosis lipoidica diabeticorum in a diabetic patient

Journal article

Lefkovits Y. and Adler A., (2019), Endocrinology, Diabetes and Metabolism Case Reports, 2019

Load More